SecBot SecBot
Insider Cluster (3 insiders) ·Filed Nov 12, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizondays Processed4d 7h ago
Insider cluster: 3 insiders, $1.7M total
Actionable Insight • Neutral

The insider sales are too small relative to market cap to signal a fundamental concern. Monitor the next 10-Q for any change in the $2.0B buyback execution pace and for further insider activity that exceeds the 0.1% of market cap threshold.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$591.17
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.56%
T+1 · $587.88
Vs SPY
+1.35%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $591.17entry
  2. T+1 · 17h ago −0.56%α +1.35% · $587.88
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three insiders at United Therapeutics sold a total of $1.67M in open-market sales within a week of the company reporting Q3 revenue above consensus but EPS below consensus due to a $130M in-process R&D charge. CEO Martine Rothblatt's sales were under a 10b5-1 plan, while director Christopher Patrusky's sale was not. The total value is 0.007% of the $25.1B market cap, well below the 0.1% threshold for materiality.

Key Financial Metrics

Direction
selling
Total Value
$1.7M
Insiders
3

Key Facts

  • Three insiders sold a total of $1.67M in open-market sales over a 7-day window ending Nov 10, 2026.
  • CEO Martine Rothblatt sold $288K under a 10b5-1 plan; EVP & General Counsel Paul Mahon sold $683K under a 10b5-1 plan; Director Christopher Patrusky sold $702K without a 10b5-1 plan.
  • Total sales represent approximately 0.007% of the $25.1B market cap, which is trivial.
  • Q3 2026 revenue of $832.5M beat the $781.1M consensus, but GAAP diluted EPS of $5.71 missed the $6.04 consensus due to a $130M in-process R&D charge from the Thymmune acquisition.
  • The company announced a new $2.0B share repurchase authorization on Nov 4, 2026.

Financial Impact

Total insider sales of $1.67M, or 0.007% of market cap, are immaterial.

Risk Factors

  • Insider sales are routine and immaterial in size; no elevated risk indicated.
  • CEO and EVP sales were under 10b5-1 plans, suggesting pre-planned liquidity, not a reaction to recent results.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1794519529202

Track record

123 reports on UTHR

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
  2. Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
  3. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Viewing Entry $591.17 Now $587.88 −0.56% settles Nov 20
  4. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  7. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
  8. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  9. Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  10. Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
Showing 10 of 123

US Market Status

Market Closed · Opens in 9h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026